NZ732197A - Gold kiwifruit compositions and methods of preparation and use therefor - Google Patents

Gold kiwifruit compositions and methods of preparation and use therefor

Info

Publication number
NZ732197A
NZ732197A NZ732197A NZ73219715A NZ732197A NZ 732197 A NZ732197 A NZ 732197A NZ 732197 A NZ732197 A NZ 732197A NZ 73219715 A NZ73219715 A NZ 73219715A NZ 732197 A NZ732197 A NZ 732197A
Authority
NZ
New Zealand
Prior art keywords
kiwifruit
gold
composition
powder
prausnitzii
Prior art date
Application number
NZ732197A
Other languages
English (en)
Inventor
Juliet Ansell
Paul Blatchford
Original Assignee
Anagenix Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anagenix Ip Ltd filed Critical Anagenix Ip Ltd
Priority to NZ769769A priority Critical patent/NZ769769B2/en
Publication of NZ732197A publication Critical patent/NZ732197A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01Instant products; Powders; Flakes; Granules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NZ732197A 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor NZ732197A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ769769A NZ769769B2 (en) 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ70245414 2014-11-28
NZ70640515 2015-03-27
PCT/NZ2015/050200 WO2016085356A1 (en) 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor

Publications (1)

Publication Number Publication Date
NZ732197A true NZ732197A (en) 2022-07-01

Family

ID=56074755

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ732197A NZ732197A (en) 2014-11-28 2015-11-27 Gold kiwifruit compositions and methods of preparation and use therefor

Country Status (16)

Country Link
US (4) US10512663B2 (enExample)
EP (2) EP4548775A3 (enExample)
JP (3) JP7330667B2 (enExample)
KR (2) KR20230156436A (enExample)
CN (3) CN106999523A (enExample)
BR (1) BR112017011078B1 (enExample)
CA (2) CA2967263A1 (enExample)
DK (1) DK3223838T3 (enExample)
ES (1) ES3023661T3 (enExample)
FI (1) FI3223838T3 (enExample)
MY (1) MY188290A (enExample)
NZ (1) NZ732197A (enExample)
PL (1) PL3223838T3 (enExample)
PT (1) PT3223838T (enExample)
SI (1) SI3223838T1 (enExample)
WO (1) WO2016085356A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512663B2 (en) * 2014-11-28 2019-12-24 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor
KR101833503B1 (ko) * 2016-12-26 2018-03-05 주식회사 엠디헬스케어 만성폐쇄성폐질환자에서 세균 메타게놈 분석을 통한 폐암 진단방법
KR101833348B1 (ko) * 2016-12-26 2018-03-02 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 유방암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
KR101942197B1 (ko) * 2016-12-28 2019-01-24 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 전립선질환 진단 방법
US11413318B2 (en) * 2017-06-06 2022-08-16 Sami-Sabinsa Group Limited Compositions and methods for management of atrophic gastritis and colitis
WO2019075273A1 (en) * 2017-10-11 2019-04-18 Gu Jennifer L INTESTINAL HEALTH COMPOSITIONS
KR102130485B1 (ko) * 2017-10-13 2020-07-06 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법
KR102007786B1 (ko) * 2017-10-18 2019-08-07 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 두경부암 진단방법
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
KR101940950B1 (ko) 2018-01-23 2019-01-21 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 담관암 진단방법
KR101944662B1 (ko) * 2018-02-14 2019-02-01 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 뇌졸중 진단방법
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
CN109288104B (zh) * 2018-11-12 2023-09-01 方家铺子(莆田)绿色食品有限公司 一种桂圆鲜果挂黄处理设备及其处理方法
US11622974B2 (en) 2019-01-18 2023-04-11 C.P. Kelco U.S., Inc. Prebiotic composition and its use
CN110279814A (zh) * 2019-06-10 2019-09-27 湖北虹玮农业有限公司 一种用于中老年慢性便秘的功能食品
US11684645B2 (en) * 2019-11-26 2023-06-27 Tci Co., Ltd. Actinidia chinensis Planch ferment and use thereof
WO2022115709A2 (en) * 2020-11-30 2022-06-02 January, Inc. Methods and composition for treating metabolic syndrome
US20220233151A1 (en) * 2021-01-22 2022-07-28 Ethicon Llc Bariatric surgery post-surgical monitoring
KR102543549B1 (ko) * 2021-01-26 2023-06-15 주식회사 다솔마임마케팅사업부 칼라만시 발포정 및 그 제조 방법
CN113521109A (zh) * 2021-06-28 2021-10-22 广州知易生物科技有限公司 解纤维素拟杆菌在预防和/或治疗炎症性肠病中的应用
CN116076711A (zh) * 2021-11-05 2023-05-09 百岳特生物技术(上海)有限公司 益生质组合物及其用途
US12343366B2 (en) * 2021-11-05 2025-07-01 Tci Co., Ltd. Prebiotic composition and method for improving intestinal health using the same
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
JP7701899B2 (ja) * 2022-09-14 2025-07-02 花王株式会社 クロロゲン酸類吸収量の予測方法
KR102536627B1 (ko) * 2022-09-30 2023-05-30 (주)바이텍 키위 발효물을 포함하는 알코올성 간손상 예방 또는 개선용 조성물
US20250195588A1 (en) * 2023-12-18 2025-06-19 First Day Life, Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
US20250195594A1 (en) * 2023-12-18 2025-06-19 First Day Life Inc. Ingestible Nutritive Compositions With Prebiotics, Probiotics, and Postbiotics
NL2038369B1 (en) * 2024-07-31 2025-03-06 Sunbird Company Ltd A composition of natural kiwifruit powder and postbiotics and its use in constipation improvement

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22355A (en) 1858-12-21 sherwood
JP2750767B2 (ja) * 1990-02-21 1998-05-13 雪印乳業株式会社 新規糖アルコール
NZ235972A (en) 1990-11-06 1995-04-27 Amaranathan Balasingham Fruit product by soft pulping after skin removal
CN1107308A (zh) * 1994-02-25 1995-08-30 中国癌症研究基金会 猕猴桃天然营养口服液
JPH10313822A (ja) * 1997-05-20 1998-12-02 Pola Chem Ind Inc 腸内細菌叢改善剤及びそれを含有する組成物
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
NZ554991A (en) * 2007-05-03 2009-11-27 Vital Food Processors Ltd Powdered kiwifruit extract compositions for the treatment of digestive dysfunction and/or gastrointestinal tract disorders
USPP22355P3 (en) * 2009-06-30 2011-12-20 Zespri Group Limited Kiwifruit plant named ‘ZESY002’
MY162344A (en) * 2010-01-28 2017-06-15 Ab-Biotics S A Probiotic composition for use in the treatment of bowel inflammation
US10512663B2 (en) * 2014-11-28 2019-12-24 Anagenix Ip Limited Gold kiwifruit compositions and methods of preparation and use therefor

Also Published As

Publication number Publication date
PT3223838T (pt) 2025-04-28
EP3223838A4 (en) 2018-08-01
US11642386B2 (en) 2023-05-09
US10512663B2 (en) 2019-12-24
CN106999523A (zh) 2017-08-01
EP3223838B1 (en) 2025-02-05
JP7330667B2 (ja) 2023-08-22
MY188290A (en) 2021-11-25
BR112017011078B1 (pt) 2021-05-11
NZ769769A (en) 2024-07-26
KR102599549B1 (ko) 2023-11-06
US20170326190A1 (en) 2017-11-16
US20220105145A1 (en) 2022-04-07
KR20230156436A (ko) 2023-11-14
JP2022078050A (ja) 2022-05-24
CA3200468A1 (en) 2016-06-02
US20200197460A1 (en) 2020-06-25
FI3223838T8 (fi) 2025-06-16
FI3223838T3 (fi) 2025-05-05
EP4548775A2 (en) 2025-05-07
JP2017537156A (ja) 2017-12-14
JP2024088715A (ja) 2024-07-02
US20240091291A1 (en) 2024-03-21
BR112017011078A2 (pt) 2017-12-26
DK3223838T3 (da) 2025-04-28
EP4548775A3 (en) 2025-08-27
ES3023661T3 (en) 2025-06-02
KR20170088970A (ko) 2017-08-02
SI3223838T1 (sl) 2025-07-31
PL3223838T3 (pl) 2025-05-26
WO2016085356A1 (en) 2016-06-02
CN116763830A (zh) 2023-09-19
US11090348B2 (en) 2021-08-17
JP7471668B2 (ja) 2024-04-22
EP3223838A1 (en) 2017-10-04
CN116270773A (zh) 2023-06-23
CA2967263A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US11642386B2 (en) Gold kiwifruit compositions and methods of preparation and use therefor
CA2973223A1 (en) Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
US20100143319A1 (en) Kiwifruit compositions
US20240293483A1 (en) Probiotic composition for the treatment of increased intestinal permeability
Stover et al. Pre-and probiotic supplementation in ruminant livestock production
US20250114412A1 (en) Methods of synbiotic treatment to improve health
KR20240038015A (ko) 신생아의 치료에서 락토바실러스 파라카세이 박테리아 균주의 용도
AU2016100499A4 (en) Yeast-containing compositions for gastrointestinal health
Gupta et al. Synbiotics: promoting gastrointestinal health
EP2365817A1 (en) Treatment
WO2021067167A1 (en) Clostrodioides difficile treatment
Sankova et al. Current drug targets for gut microbiota biocorrection during the SARS-CoV-2 pandemic: A systematic review
US20250041365A1 (en) Probiotic compositions and microbial consortia to improve human organ system health
Singh et al. Probiotics in Pediatric and Neonate Healthcare
SP Effects of Resveratrol in a Mouse Model of Alcohol Addiction
CN119584976A (zh) 用于治疗肠道微生物群失衡的组合物
HK40065763A (zh) 产生短链脂肪酸的益生菌菌株和包含该益生菌菌株的组合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2023 BY COMPUTER PACKAGES INC

Effective date: 20221030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2024 BY COMPUTER PACKAGES INC

Effective date: 20231030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2025 BY COMPUTER PACKAGES INC

Effective date: 20241030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2026 BY COMPUTER PACKAGES INC

Effective date: 20251030